YaleNewHaven**Health**

Smilow Cancer Hospital



Grand Rounds

Friday, June 14, 9:00am

Synthetic Lethal Therapy for HPV-Negative Head and Neck Cancer

featuring

Barbara Burtness, MD

Anthony N. Brady Professor of Medicine (Medical Oncology); Chief Translational Research Officer, Yale Cancer Center; Chief, Head and Neck Cancers/Sarcoma


55 Park Street Auditorium I Zoom Access Continental breakfast will be available

Needs: There have been many advancements in how molecular biology has allowed us to treat cancer and there is a need to discuss how synthetic lethal therapy is being used for HPV-Negative head and neck cancer.

Objectives: Discuss synthetic lethal therapeutic strategies in HPV-negative head and neck cancer. Share advances in molecular biology to better treat patients with head and neck cancers.







Dr. Burtness is internationally recognized for her research in head and neck cancer. She is a Professor of Medicine (Medical Oncology), Chief Translational Research Officer, and Associate Cancer Center Director for Translational Research and serves as Co-Leader of the Developmental Therapeutics Program, is Division Chief for Head and Neck/Sarcoma Oncology, and is Director of the Yale Head and Neck SPORE.

Dr. Burtness chairs the ECOG-**ACRIN** Cooperative Group Head and Neck Cancer Therapeutics Committee and the ECOG-ACRIN Task Force for the Advancement of Women, and leads national and international trials of targeted therapy in head and neck cancer. Her lab studies synthetic lethal therapeutic strategies in head and neck cancer and the targeting of aurora kinase A to overcome adaptive resistance to EGFR inhibition and direct KRAS inhibition in lung cancer.

There is No Corporate Support for These Activities. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Designation Statement: The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Target Audience: YCC members, Smilow faculty, YSM, Nursing, Public Health Students. Faculty Disclosures: Winer- nothing to disclose. Burtness-none. Financial support for serving on an Independent Data Review Committee for Cogent Biosciences. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. Mitigation of Financial Relationships Statement: Yale CME adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.